Literature DB >> 15531032

Safety of the yellow fever vaccine during the September 2001 mass vaccination campaign in Abidjan, Ivory Coast.

Julia Fitzner1, Daouda Coulibaly, Daniel Ekra Kouadio, Jean Claude Yavo, Yao Guillaume Loukou, Paul Odehouri Koudou, Denis Coulombier.   

Abstract

In 2001, a vaccination campaign against yellow fever was carried out in Abidjan, Cote d'Ivoire. During the campaign and 4 weeks after an active surveillance system for adverse events following immunization (AEFI) was set up. More then 2.6 million doses were administered and 87 AEFI were notified. Eight suspected YF cases were reported after vaccination and considered as AEFI. However, none had IgM for YF and all recovered without sequels. This surveillance system provided reassuring data about the safety of the YF vaccine and proved that it is feasible to set up an active surveillance system during a mass campaign.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15531032     DOI: 10.1016/j.vaccine.2004.05.018

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  3 in total

Review 1.  Questions regarding the safety and duration of immunity following live yellow fever vaccination.

Authors:  Ian J Amanna; Mark K Slifka
Journal:  Expert Rev Vaccines       Date:  2016-06-20       Impact factor: 5.683

2.  Yellow fever control in Cameroon: where are we now and where are we going?

Authors:  Charles Shey Wiysonge; Emmanuel Nomo; Jeanne Mawo; James Ofal; Julienne Mimbouga; Johnson Ticha; Peter M Ndumbe
Journal:  BMC Med       Date:  2008-02-08       Impact factor: 8.775

3.  Children who received PCV-10 vaccine from a two-dose vial without preservative are not more likely to develop injection site abscess compared with those who received pentavalent (DPT-HepB-Hib) vaccine: a longitudinal multi-site study.

Authors:  Yemane Berhane; Alemayehu Worku; Meaza Demissie; Neghist Tesfaye; Nega Asefa; Worku Aniemaw; Berhe Weldearegawi; Yigzaw Kebede; Tigist Shiferaw; Amare Worku; Lemessa Olijira; Behailu Merdekios; Yemane Ashebir; Takele Tadesse; Yadeta Dessie; Solomon Meseret; Gestane Ayele
Journal:  PLoS One       Date:  2014-06-04       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.